Telomerase Inhibitor: Promising Target Therapy for Cancer

Diana Kusuma (Oncology Gynecology Division, Obstetrics and Gynecology Department, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia)
Izza Aliya (Oncology Gynecology Division, Obstetrics and Gynecology Department, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia)
Andre Putra (Oncology Gynecology Division, Obstetrics and Gynecology Department, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia)
Mediana Sutopo (Obstetrics and Gynecology Department, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia)

Cermin Dunia Kedokteran
Vol 45, No 4 (2018): Cedera Kepala

The key to selectively targeting cancer cells is to exploit some basic differences with their normal precursors. One such difference is the activity of the enzyme telomerase. Some studies targeted telomerase and telomeres in order to block limitless replicative potential of cancer cells, providing a fascinating strategy for a broad-spectrum cancer therapy. Telomerase based therapies could be well tolerated and perhaps with minimal side effect on telomerase-competent stem cells.Kunci pengobatan selektif sel kanker adalah dengan memanfaatkan beberapa perbedaan mendasar antara prekursor sel kanker dengan sel normal tubuh. Salah satu perbedaannya adalah aktivitas enzim telomerase. Beberapa penelitian sudah menargetkan telomerase dan telomer sebagai target terapeutik untuk memblokir potensi replikasi sel kanker yang tak terbatas, sebagai strategi terapi kanker spektrum luas. Terapi berbasis telomerase ini dapat ditoleransi dengan baik dan memiliki efek samping minimal pada telomerase sel normal tubuh lainnya.